Josh Disbrow has been in the life sciences industry for nearly twenty-five years across pharmaceuticals, diagnostics, and medical devices. Josh co-founded Aytu BioPharma in 2015 and took the company public, having led Aytu’s listing on NASDAQ in 2017. 

Prior to co-founding Aytu, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE), a clinical-stage biotechnology company developing anti-inflammatory biological therapies. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals, a private specialty pharmaceutical company.

Josh joined Arbor Pharmaceuticals as the company’s second employee and oversaw the launch and subsequent growth of the company’s commercial operations. Josh led the commercial organization since the company’s inception and led the launch of the company’s first product, subsequently launching numerous products and scaling the commercial organization across sales, marketing, managed care, sales training, and national accounts. In less than five years, Arbor grew from a company from the pre-commercialization stage and grew product sales to over $250 million. 

Prior to joining Arbor, he served as the Director of Marketing at LipoScience (NASDAQ: LPDX), a specialty cardiovascular diagnostic company later acquired by LabCorp (NYSE: LH). Previously, Josh was in sales leadership at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices.

Josh began his career as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc). Josh currently sits on the Board of Directors and is the Chair of the Nominating and Governance Committee of Zynex, Inc. (NASDAQ: ZYXI), a medical device company focused on electrotherapy and pain management. He holds a Bachelor of Science in Management from North Carolina State University and a Master of Business Administration from Wake Forest University.

Mr. Eisenstadt most recently was Chief Financial Officer at Neos Therapeutics, Inc. where he raised over $340 million in private and public equity and debt financings and supported the transition of the company from clinical stage to commercial operations prior to its merger with Aytu in March 2021. Prior to Neos, Mr. Eisenstadt served as Chief Financial Officer at Arborgen, Inc. from 2013 to 2014, and prior to that, as Chief Financial Officer at Tranzyme, Inc., where he led its IPO, negotiated several licensing agreements and financed the company through late-stage clinical development. Mr. Eisenstadt received an M.B.A. from James Madison University and a B.A. in Economics from the University of North Carolina at Chapel Hill.

Prior to joining Aytu BioPharma at the closing of the company’s merger with Neos Therapeutics in March 2021, Greg Pyszczymuka served as Vice President, Commercial at Neos Therapeutics since June 2020. He previously served as Vice President, Commercial Strategy & Market Access at Neos from November 2018 to June 2020 and as Executive Director of Channel Strategy & Access Programs. Prior to joining Neos, Greg has served in roles of increasing responsibility over a 15-year career including sales management, brand management, channel strategy, managed markets and new products planning. Greg joined Neos most recently from Aqua Pharmaceuticals (an Almirall company) and previously was with Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.

Jarrett Disbrow is a seasoned pharmaceutical entrepreneur having been the founder of three pharmaceutical and life sciences companies over the past decade and broad industry experience spanning over twenty years.

Most recently and prior to forming Aytu BioPharma in April 2015, Jarrett was the President & CEO of Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on male sexual dysfunction. Mr. Disbrow’s first pharmaceutical start-up was Arbor Pharmaceuticals, a company focused initially on pediatrics. As the sole founder of Arbor, Jarrett was responsible for the vision, fundraising, start-up, strategy and growth of the company until the acquisition by an investor group in 2010. Prior to founding Arbor Pharmaceuticals, he was head of marketing for Accentia Biopharmaceuticals, Inc. Jarrett began his career with GlaxoWellcome (now GlaxoSmithKline plc) where he held various roles in sales and marketing. He received a B.S. in Business Management from North Carolina State University in Raleigh, NC.

Matthew V. Phillips is a business leader and commercial executive who has held progressive leadership positions at numerous healthcare companies over his twenty-five-plus year career. Most recently, Matt served as the Chief Commercial Officer of Cerecor, Inc. (NASDAQ: CERC), where he led all aspects of commercial operations and built a profitable pediatric commercial business unit.

In Matt’s executive role at Cerecor, he reported to the Chief Executive Officer and Board of Directors and maintained responsibilities beyond leading the commercial team. His responsibilities also included business development, collaboration with research and development, leading product and company acquisition processes, and leading market development in preparation for commercialization of multiple orphan drug candidates.

Prior to Cerecor, Matt was the President and Chief Operating Officer of Zylera Pharmaceuticals, which was acquired by Cerecor in 2017. Matt ran all aspects of commercial operations at Zylera and built a high-performing, entrepreneurial commercial organization that experienced rapid growth during his tenure. Previous to joining Zylera, Matt served as Executive Director of Managed Markets and Corporate Accounts at Victory Pharmaceuticals, where he developed and oversaw all aspects of reimbursement, distribution, and government accounts.

Earlier in his pharmaceutical career, Matt was an integral member of the management teams at Dura Pharmaceuticals and Eisai, Inc. Matt began his career in the home health care industry where he held progressive positions in sales and sales management.

Nate Massari joined the Aytu BioPharma executive team in April 2021 upon the acquisition of the global license to AR101 (enzastaurin) from Rumpus Therapeutics. Nate has more than 20 years of healthcare experience in consulting, in-line marketing and sales, pipeline marketing, corporate strategy, sales management and corporate development across the pharmaceutical, biotech, device, health services, and distribution industries. He began his career in management consulting within the Health & Life Sciences practice at Accenture. Nate also held various leadership roles at Johnson & Johnson, AstraZeneca, Endo Pharmaceuticals, and AmerisourceBergen. He has completed numerous business development transactions totaling over $6 billion in capital deployment, and his rare disease expertise includes launching pediatric inflammatory bowel disease indications while at Johnson & Johnson as well as leading the orphan drug pediatric endocrinology franchise at Endo Pharmaceuticals. Most recently, Nate co-founded Rumpus Therapeutics to develop new medicines for pediatric onset rare and orphan diseases. Nate has a BA from Princeton University and an MBA from the Wharton School at the University of Pennsylvania.

Topher Brooke joined the Aytu BioPharma executive team in April 2021 upon the acquisition of the global license to AR101 (enzastaurin) from Rumpus Therapeutics. Topher has over 20 years of general management experience in healthcare across all phases of development and commercialization. He has depth of experience from target selection and clinical development planning through running several blockbuster commercial pharmaceutical franchises. He has worked across several modalities (proteins, small molecules and vaccines) and across multiple therapeutic areas. Topher has held roles of increasing responsibility at Johnson & Johnson, AstraZeneca, and AmerisourceBergen. His rare disease experience includes launching pediatric inflammatory bowel disease indications while at Johnson & Johnson as well as leading the pediatric infectious disease franchise at AstraZeneca. Topher went on to lead the fully integrated Diabetes Division at AstraZeneca. Most recently, Topher co-founded Rumpus Therapeutics to develop new medicines for pediatric onset rare and orphan diseases. Topher has a BA from Colgate University and an MBA from the Wharton School at the University of Pennsylvania.

Russ McMahen has 30 years of industry experience specializing in the development of solid, liquid and suspension dosage forms. Mr. McMahen is the co-inventor of the DTRS® and RDIM™ ion exchange delivery technologies that were utilized to develop the modified release microparticles that are used in Aytu BioPharma’s products. Prior to joining Aytu BioPharma upon the merger with Neos Therapeutics in 2021, Mr. McMahen held various positions including Senior Vice President, Research & Development, Executive Vice President of Operations and Vice President of Scientific Affairs. Prior to joining Neos, Mr. McMahen served at Zenith/Goldline Laboratories which was subsequently acquired by Ivax Pharmaceuticals. He has a B.S. in Chemical Engineering from Louisiana Tech University.

Margaret Cabano has served as the Vice President of Operations for Aytu BioPharma since the merger of Aytu BioScience and Neos Therapeutics in 2021. Ms. Cabano held the same role for Neos Therapeutics since 2005. She has 21 years of industry experience and leads all aspects of manufacturing operations, including supply chain, engineering, and technical services. Prior to joining Neos, Ms. Cabano worked in operations and supply chain management for Adams Respiratory Therapeutics and Cardinal Health. Ms. Cabano holds an M.B.A. in Operations Management Science and a B.A. in Supply Chain Logistics from the University of North Texas.

Suzane Kennedy is an experienced Regulatory Affairs and Quality Assurance leader in the life sciences industry. She has worked over 20 years across pharmaceuticals, dietary supplements, and medical devices. Most recently and prior to joining Aytu BioScience in June 2018, Suzane was the Director of Quality Assurance with a start-up bioscience company, Armis Biopharma that focused on a combination product coming to market. Suzane started her career as a Quality Control Chemist at Upsher-Smith Laboratories and was promoted quickly into a management role. In order to continue her growth in the life science’s field Suzane moved into the medical device regulatory, including roles with ConMed Corporation and Cochlear Americas. She received a B.S. in Chemistry at Metro State University in Denver Colorado.

Josh Disbrow has been in the life sciences industry for nearly twenty-five years across pharmaceuticals, diagnostics, and medical devices. Josh co-founded Aytu BioPharma in 2015 and took the company public, having led Aytu’s listing on NASDAQ in 2017.

Prior to co-founding Aytu, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE), a clinical-stage biotechnology company developing anti-inflammatory biological therapies. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals, a private specialty pharmaceutical company.

Josh joined Arbor Pharmaceuticals as the company’s second employee and oversaw the launch and subsequent growth of the company’s commercial operations. Josh led the commercial organization since the company’s inception and led the launch of the company’s first product, subsequently launching numerous products and scaling the commercial organization across sales, marketing, managed care, sales training, and national accounts. In less than five years, Arbor grew from a company from the pre-commercialization stage and grew product sales to over $250 million. 

Prior to joining Arbor, he served as the Director of Marketing at LipoScience (NASDAQ: LPDX), a specialty cardiovascular diagnostic company later acquired by LabCorp (NYSE: LH). Previously, Josh was in sales leadership at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices.

Josh began his career as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc). Josh currently sits on the Board of Directors and is the Chair of the Nominating and Governance Committee of Zynex, Inc. (NASDAQ: ZYXI), a medical device company focused on electrotherapy and pain management. He holds a Bachelor of Science in Management from North Carolina State University and a Master of Business Administration from Wake Forest University.

Mr. Boyd is the Founder and Chief Investment Officer of Armistice Capital, a healthcare equity hedge fund he founded in 2012. Prior to founding Armistice, Mr. Boyd was a Research Analyst at Senator Investment Group, York Capital, and SAB Capital Management, where he focused on healthcare. Mr. Boyd began his career as an Analyst at McKinsey & Company.

Mr. Boyd has served as a member of the board of directors of Cerecor (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare, since April 2017 and EyeGate Pharmaceuticals (NASDAQ: EYEG), a clinical-stage, specialty pharmaceutical company focused on disorders of the eye, since May 2018. Mr. Boyd received a B.S. in Economics and a B.A. in Political Science from The Wharton School of the University of Pennsylvania.

Gary Cantrell has thirty years’ experience in the life sciences industry ranging from clinical experience as a respiratory therapist to his current executive consulting business as Principal of Averaden, LLC. Prior to forming his professional consultancy, Gary served as CEO of Yasoo Health Inc., a global specialty nutritional company from 2007 to 2015, highlighted by the sale of its majority asset, AquADEKs, to Actavis in March 2015.

He was also president of the Catevo Group, a North Carolina-based healthcare consulting firm, and Executive Vice President, Sales and Marketing at TEAMM Pharmaceuticals, an Accentia Biopharmaceuticals company. Mr. Cantrell started his pharmaceutical career at GSK, where he held multiple senior management positions in sales, marketing and business development over a period of 22 years. He has served as an advisor or board member of several emerging life science companies including his previous role as a board member at Flexible Stenting Solutions, Inc., which was sold to Cordis, while a division of Johnson & Johnson in March 2013. Mr. Cantrell is a graduate of Wichita State University.

Carl Dockery is a financial executive with many years of experience in the insurance and reinsurance industry and more recently in 2006 as the founder of a registered investment advisory firm, Alpha Advisors, LLC. Carl’s 20-year career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as Vice President of Gulf Insurance Co. Ltd. of Grand Cayman.

Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd’s and the London Underwriting Centre brokering various types of reinsurance placements. Carl was formerly a member of the Board of Directors of CytoDyn, Inc., a publicly traded biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection and is an active investor in various healthcare companies through Alpha Ventures, the venture capital affiliate of Alpha Advisors. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities.

John Donofrio has over 25 years of experience in leading US and International teams in the pharmaceutical industry. John is a trusted finance leader with a proven track record of building strategy, financial management, leading teams, business partnering and strong collaboration among all levels of an organization.

John has served as President of EPI Health since March of 2019. EPI Health is a growing specialty company based in Charleston, South Carolina with a focus on dermatology. Previously John served as Chief Financial Officer at TrialCard, a technology-enabled, pharmaceutical solutions company. Prior to joining TrialCard, John served as the Chief Financial Officer at Merz North America where he was responsible for overall strategy, management, reporting and controls of financial performance. He also lead the commercial analytics, data management, forecasting and operational excellence teams. Previous to Merz, John spent over 20 years at GSK in various U.S. and international roles of increasing responsibility and scope including commercial operations controlling, statutory accounting, manufacturing and supply, mergers and acquisition integration. John holds a bachelor’s degree in accounting from North Carolina State University and serves on the board of directors for Alliance Medical Ministries and Children’s Skin Disease Foundation.

Michael Macaluso is the Chairman and Chief Executive Officer of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE). Mike founded Ampio Pharmaceuticals in 2010 through a merger with DMI Life Sciences, and he has been Chairman of the Board of Directors since the company’s inception.

Mike was appointed Ampio’s Chief Executive Officer in January 2012 and has advanced the company’s preclinical development assets into late-stage clinical trials whereby Ampio is now engaged in the second US pivotal study with its lead therapeutic agent Ampion, a novel biologic being studied for the treatment of osteoarthritis of the knee. Prior to founding Ampio Mike was President, Chief Executive Officer, and a member of the Board of Directors of Isolagen, Inc. (AMEX: ILE), a biotechnology company.  From October 1998 until June 2001, Mike was the owner of Page International Communications, a global manufacturing business. Mike was also a founder and principal of International Printing and Publishing, a position Mike held from 1989 until 1997, when he sold that business to a private equity firm.  Mike is a graduate of Canisius College.